Medical experts discuss several topics pertaining to the evolving treatments in HR+/HER2- advanced breast cancer, including unmet needs and the integral role of pharmacists in patient care.
EP. 1: Disease Factors Influencing Treatment Pathways For HR+/HER2- Advanced Breast Cancer
Dr Ryan Haumschild, PharmD, MS, MBA, leads a discussion focused on HR-positive, HER2-negative treatment in advanced-stage breast cancer.
EP. 2: Successful Clinical Outcomes With Treatment in Advanced-Stage Breast Cancer
Heather N. Moore, PharmD, BCOP, CPP, and Susan Faye Dent, MD, FRCPC, FICOS, emphasize the critical role of the pharmacist in achieving clinical endpoints in advanced-stage breast cancer.
EP. 3: The Impact of Pharmacists in Treatment Pathways of HR+/HER2- Breast Cancer
The panel of experts explore the contribution provided by pharmacists in the treatment landscape of patients with HR-positive, HER2-negative breast cancer.
EP. 4: Impact of SERD/SERM Development in Treatment Landscape for Breast Cancer
Drs Moore and Dent discuss the impact of oral selective estrogen receptor degraders and modulators in the treatment for HR-positive, HER2-negative breast cancer.
EP. 5: Treatment Options in Patients With PIK3CA Mutation
Susan Faye Dent, MD, FRCPC, FICQS, provides an overview of the BYLieve study and the impact on treatment options in patients with HR+, HER2- breast cancer.
EP. 6: Utilizing Multidisciplinary and Patient-Centered Care to Manage Drug Toxicity
Utilizing Multidisciplinary and Patient-Centered Care to Manage Drug Toxicity
EP. 7: Emerging Treatment Pathways For Management of HR+/HER2- Breast Cancer
The panel explore emerging treatment pathways in HR+/HER2- breast cancer and the impacts on care management and patient outcomes.
EP. 8: Pharmacist-Driven Treatment Options for Patients With HR+/HER2- Breast Cancer
Heather N. Moore, PharmD, BCOP, CPP, drives a discussion on the role of pharmacists in treatment strategy and optimizing patient adherence to HR+/HER2- breast cancer treatment.
EP. 9: Addressing Disparities in Clinical Trial Settings
The panel highlights opportunities for inclusive populations within trials for HR+/HER2- breast cancer, as well as pharmacist-led initiatives in clinical trial settings.
EP. 10: Target Outcomes in HR+/HER2- Treatment Management
Insights on unmet needs in HR-positive, HER2-negative treatment management and on how pharmacists can optimize treatment strategies and patient outcomes.
EP. 11: Emphasizing Electronic Medical Records in Toxicity Management
Exploring the significant role of electronic medical records (EMR) in toxicity management for patients with HR+/HER2– breast cancer.
EP. 12: Anticipated Updates in HR+/HER2- Treatment Options
Experts share forthcoming treatment options in the treatment of HR+/HER2– breast cancer.
EP. 13: Optimizing Current Therapies and Maintaining Quality of Life in HR+/HER2- Breast Cancer Treatment
Drs Haumschild, Moore, and Dent provide strategies to optimize current and forthcoming HR+/HER2– breast cancer therapies while preserving patients’ quality of life.
EP. 14: Factors Guiding Treatment of HR+/HER2- Breast Cancer
Wassim McHayleh, MD, MBA, FACP, and Alisa Vinokurov, PharmD, discuss HR+/HER2- breast cancer.
EP. 15: Evolution of Pharmacist Role in Treatment and Management of Breast Cancer
Dr Vinokurov illustrates the evolving role of pharmacists in HR+/HER2- breast cancer treatment.
EP. 16: Pharmacist Involvement in Treatment Management for Breast Cancer
Alisa Vinokurov, PharmD, and Wassim McHayleh, MD, MBA, FACP, discuss pharmacists’ evolving role in treatment management for breast cancer.
EP. 17: Current Treatment Landscape for HR+/HER2- Breast Cancer
Dr McHayleh provides an overview of HR+/HER2- breast cancer treatment strategies and practices.
EP. 18: Toxicity Management in Breast Cancer Treatment
Drs McHayleh and Vinokurov discuss toxicity management associated with breast cancer treatments.
EP. 19: Pharmacist Support in Management of HR+/HER2- Breast Cancer
Clinical pharmacists play a significant role in treatment management of patients with HR+/HER2- breast cancer.
EP. 20: Evaluating Evidence in HR+/HER2- Breast Cancer Treatment Landscape
Drs Vinokurov and McHayleh discuss the impact of clinical trials on the treatment landscape of HR+/HER2- breast cancer.
EP. 21: Comparing HR+/HER2- Breast Cancer in Academic and Community Health Settings
Drs Vinokurov and McHayleh discuss how the approach to breast cancer treatment may vary between academic and community health settings.
EP. 22: Anticipated Developments on the Horizon for Patients With HR+/HER2- Breast Cancer
Expert panelists discuss potential coming developments in the treatment landscape for breast cancer.
EP. 23: Trajectory of HR+/HER2- Breast Cancer Treatment
Drs McHayleh and Vinokurov share final thoughts, highlighting the future of treatment for HR+/HER2- breast cancer.
2 Clarke Drive Cranbury, NJ 08512